Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Financial Condition

v3.19.2
Liquidity and Financial Condition
9 Months Ended
Apr. 30, 2019
Liquidity And Financial Condition  
Liquidity and Financial Condition

Note 3—Liquidity and Financial Condition

 

The Company has sustained losses in all reporting periods since inception, with an inception-to-date loss of $156.9 million as of April 30, 2019, which raises substantial doubt. Further, the Company has never generated any cash from its operations and does not expect to generate meaningful cash in the near term. Consequently, the Company will need additional capital to continue operating its business and fund its planned operations, including research and development, clinical trials and, if regulatory approval is obtained, commercialization of its product candidates. In addition, the Company will require additional financing if it desires to in-license or acquire new assets, research and develop new compounds or new technologies and pursue related patent protection, or obtain any other intellectual property rights or other assets.

 

As of April 30, 2019, the Company had cash, cash equivalents and investment securities of $23.3 million. The Company had cash of $4.2 million and cash equivalents of $18.1 million for a total cash and cash equivalents balance of $22.3 million. In addition, the Company had short-term investment securities of $1.0 million. Cash flows from financing activities continued to provide the primary source of our liquidity. Net cash provided by financing activities was $17.2 million during the nine months ended April 30, 2019, which was primarily attributable to the net proceeds received from the Alpha Holdings agreement, Aspire Capital agreement and the exercise of certain stock options (See Note 7).

 

Additionally, subsequent to April 30, 2019, the Company received gross proceeds of approximately $11.0 million from the sale of our common stock and warrants. (see Note 12). As of May 28, 2019, the Company had cash, cash equivalents and investment securities of approximately $31.4 million.

 

The above financing activities substantially increased the Company’s cash position. As a result, as of the date of the issuance of these condensed consolidated financial statements, the Company believes its current cash position as a result of the Company’s financing activities during the nine months ended April 30, 2018 and through June 2019 has alleviated substantial doubt about its ability to sustain operations through at least the next 12 months from the issuance date of the condensed consolidated financial statements. The Company is anticipating raising additional capital but there can be no assurance that it will be able to do so or if the terms will be favorable.